Close Menu

non-small cell lung cancer

The firm will use its REFS platform to create in silico network models that will be used in simulations that connect drug doses to transcriptional and imaging measurement networks.

GNS will use its REFS platform to analyze data from NCI in the hopes of identifying biomarkers that can help guide treatments for NSCLC patients.

Pfizer will issue a sub-license to Abbott to develop diagnostic products to screen NSCLC tumors for the presence of rearrangements in the ALK gene.

John Castellani, CEO of the Pharmaceutical Research and Manufacturers of America, said that while the industry's commitment to using genomic strategies to advance targeted therapies is growing, the road ahead is fraught with scientific, regulatory, and reimbursement challenges.

Data presented at ASCO this week showed that NSCLC patients with EGFR mutations who received Tarceva lived twice as long without their disease progressing compared to patients who received platinum-based chemotherapy, which is currently the standard of care for first-line NSCLC therapy.

"The median progression-free survival [with crizotinib] far exceeds anything that one would expect with standard therapy in this heavily pretreated group," Nasser Hanna of Indiana University said in a presentation at ASCO reviewing interim Phase I data on the drug.

The assay will be for CO-1686, which is currently in pre-clinical development for advanced non-small cell lung cancer patients.

In preliminary studies, "researchers observed a tumor size reduction of up to 76 percent over a treatment period of up to five months" in patients who had acquired resistance to standard tyrosine kinase inhibitors.

Shortly after Pfizer's regulatory filings for the NSCLC ALK-inhibitor crizotinib in these two countries, Abbott submitted its premarket approval application with US and Japanese regulatory authorities for a FISH-based companion diagnostic test.

The test is being used in clinical trials with Pfizer's crizotinib, an anaplastic lymphoma kinase inhibitor.


Two COVID-19 vaccine developers have released their trial protocols to build public trust, the New York Times reports.

A new analysis finds the rapid COVID-19 test from DnaNudge to be highly accurate, Reuters reports.

In Science this week: global citizens' assembly on genome-editing technologies proposed, epigenetic markers predict metformin response, and more.

According to the Verge, many US states are not including positive results from rapid COVID-19 testing in their case numbers.